Opis projektu
Czechy tworzą Centrum Doskonałości Farmacji w zakresie zaawansowanych technologii
Kwasy nukleinowe, w tym DNA i RNA, wykazały ekscytujący potencjał w leczeniu wielu chorób, nie wspominając o ich zastosowaniu w szczepionkach, co zostało udowodnione podczas pandemii COVID-19. Wyzwaniem pozostaje jednak ukierunkowany transport kwasów do określonych tkanek i komórek. Problem ten może rozwiązać Wydział Farmacji Uniwersytetu Masaryka w Czechach. W ramach finansowanego przez UE projektu ExcellPharmTech zatrudniona zostanie katedra Europejskiej Przestrzeni Badawczej, która utworzy Centrum Doskonałości Farmacji w zakresie zaawansowanych technologii, intensyfikując badania i rozwój. Celem prowadzonych prac będzie umożliwienie ukierunkowanego dostarczania kwasów nukleinowych do komórek docelowych i rozwijania partnerstw strategicznych na potrzeby szybszego wprowadzenia zaawansowanych leków do ośrodków.
Cel
Masaryk University (MU) is the second-largest university in the Czech Republic located in Brno. Thanks to the ESIF funding, MU was able to acquire top research infrastructure attracting talented researchers who gradually built the position of the MU as the top regional hub for education, research, and innovation.
To further exploit this potential, the management structures and processes of the university must thoroughly implement the European Research Area (ERA) Priorities. As an outstanding researcher/innovator can have a decisive and positive impact on the culture and performance of any institution, MU will recruit a world-class research manager as an ERA Chair for its newly-established Faculty of Pharmacy.
The Faculty of Pharmacy (MUNI Pharm) is, besides others, focused on the development of advanced drug formulations and molecular biology techniques. The ERA Chair will intensify the research and development of advanced drug formulation and nanotechnologies to open new opportunities to intensify MUNI Pharm research capacities in the field of pharmacy and develop strategic partnerships with the application sphere and public sector for faster translation of the advanced drugs into clinics.
The recruitment of leading scientist will enforce the connection of the MUNI Pharm to research structures of MU, and the ERA Chair will make a bridge in the formation of unique education and research facility at one place titled MUNI BioPharma Hub, supported from National Recovery Plan (part of RRF – Recovery and Resilience Facility, NextGeneration EU).
To solve the targeted delivery and transportation of nucleic acids into target cell environment, the MUNI Pharm will establish an interdisciplinary center of excellence (Pharma Center of Excellence in Advanced Technology) with prof. David Oupický as its leader. The creation of an international ERA Chair team will ensure a successful establishment of the center combining excellent research, high level education and top innovations.
Dziedzina nauki
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- social scienceseconomics and businessbusiness and managementinnovation management
- engineering and technologynanotechnology
- medical and health sciencesbasic medicinepharmacology and pharmacy
- natural sciencesbiological sciencesmolecular biology
Słowa kluczowe
Program(-y)
Zaproszenie do składania wniosków
HORIZON-WIDERA-2022-TALENTS-01
Zobacz inne projekty w ramach tego zaproszeniaSystem finansowania
CSA - Coordination and support actionKoordynator
601 77 Brno
Czechy